Mizuho Maintains Outperform on Haemonetics, Lowers Price Target to $70

Benzinga Newsdesk www.benzinga.com Negative 95.6%

Neg 95.6% Neu 0% Pos 0%

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and lowers the price target from $80 to $70.